| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:PAX3-NCOA2 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: PAX3-NCOA2 | FusionPDB ID: 62943 | FusionGDB2.0 ID: 62943 | Hgene | Tgene | Gene symbol | PAX3 | NCOA2 | Gene ID | 5077 | 10499 |
| Gene name | paired box 3 | nuclear receptor coactivator 2 | |
| Synonyms | CDHS|HUP2|WS1|WS3 | GRIP1|KAT13C|NCoA-2|SRC2|TIF2|bHLHe75 | |
| Cytomap | 2q36.1 | 8q13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | paired box protein Pax-3paired box homeotic gene 3paired domain gene 3paired domain gene HuP2transcriptional factor PAX3 | nuclear receptor coactivator 2class E basic helix-loop-helix protein 75glucocorticoid receptor-interacting protein-1p160 steroid receptor coactivator 2transcriptional intermediary factor 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | PAXBP1 | Q15596 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000336840, ENST00000344493, ENST00000350526, ENST00000392069, ENST00000392070, ENST00000409551, ENST00000464706, ENST00000258387, ENST00000409828, | ENST00000267974, ENST00000524223, ENST00000452400, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 7 X 10 X 5=350 | 19 X 24 X 6=2736 |
| # samples | 8 | 12 | |
| ** MAII score | log2(8/350*10)=-2.12928301694497 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/2736*10)=-4.51096191927738 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: PAX3 [Title/Abstract] AND NCOA2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | |||
| Anticipated loss of major functional domain due to fusion event. | PAX3-NCOA2 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. PAX3-NCOA2 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PAX3 | GO:0045893 | positive regulation of transcription, DNA-templated | 11863357 |
| Hgene | PAX3 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11863357 |
| Fusion gene breakpoints across PAX3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across NCOA2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerKB3 | . | . | PAX3 | chr2 | 223084858 | - | NCOA2 | chr8 | 71057083 | - |
| ChimerKB3 | . | . | PAX3 | chr2 | 223084858 | - | NCOA2 | chr8 | 71060718 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000392069 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7410 | 1539 | 366 | 3539 | 1057 |
| ENST00000344493 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7425 | 1554 | 381 | 3554 | 1057 |
| ENST00000350526 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7181 | 1310 | 137 | 3310 | 1057 |
| ENST00000336840 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7425 | 1554 | 381 | 3554 | 1057 |
| ENST00000392070 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7425 | 1554 | 381 | 3554 | 1057 |
| ENST00000409551 | PAX3 | chr2 | 223084858 | - | ENST00000452400 | NCOA2 | chr8 | 71060718 | - | 7321 | 1450 | 280 | 3450 | 1056 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >62943_62943_1_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000336840_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1057AA_BP=390 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEES EKKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNR RARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTR HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRP TMPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWP ESILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLE QKAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVN LTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATN -------------------------------------------------------------- >62943_62943_2_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000344493_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1057AA_BP=390 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEES EKKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNR RARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTR HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRP TMPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWP ESILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLE QKAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVN LTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATN -------------------------------------------------------------- >62943_62943_3_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000350526_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1057AA_BP=390 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEES EKKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNR RARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTR HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRP TMPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWP ESILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLE QKAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVN LTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATN -------------------------------------------------------------- >62943_62943_4_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000392069_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1057AA_BP=390 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEES EKKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNR RARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTR HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRP TMPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWP ESILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLE QKAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVN LTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATN -------------------------------------------------------------- >62943_62943_5_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000392070_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1057AA_BP=390 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEES EKKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNR RARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTR HGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRP TMPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWP ESILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLE QKAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVN LTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATN -------------------------------------------------------------- >62943_62943_6_PAX3-NCOA2_PAX3_chr2_223084858_ENST00000409551_NCOA2_chr8_71060718_ENST00000452400_length(amino acids)=1056AA_BP=389 MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRPLPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRY QETGSIRPGAIGGSKPKVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSVSSISRILRSKFGKGEEEEADLERKEAEESE KKAKHSIDGILSERASAPQSDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREELAQRAKLTEARVQVWFSNRR ARWRKQAGANQLMAFNHLIPGGFPPTAMPTLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSSSAYCLPSTRH GFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEEILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVGA QKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNSSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRPT MPSGEWAPQSSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMNIGPSELEMNMGGPQYSQQQAPPNQTAPWPE SILPIDQASFASQNRQPFGSSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQSQAVDPEQFSSQDSNIMLEQ KAPVFPQQYASQAQMAQGSYSPMQDPNFHTMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMNQISNVSNVNL TLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQVQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGIS QQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATNT -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:/chr8:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PAX3 | NCOA2 |
| 917 | FUNCTION: Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC1 expression. Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3. Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-ARNTL/BMAL1 heterodimer (By similarity). {ECO:0000250|UniProtKB:Q61026, ECO:0000269|PubMed:23508108, ECO:0000269|PubMed:9430642}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
| PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
| PDB file (780) >>>780.pdbFusion protein BP residue: 389 CIF file (780) >>>780.cif | PAX3 | chr2 | 223084858 | - | NCOA2 | chr8 | 71060718 | - | MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRP LPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRYQETGSIRPGA IGGSKPKVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPSV SSISRILRSKFGKGEEEEADLERKEAEESEKKAKHSIDGILSERASAPQS DEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTREE LAQRAKLTEARVQVWFSNRRARWRKQAGANQLMAFNHLIPGGFPPTAMPT LPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDSS SAYCLPSTRHGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLEE ILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVGA QKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRNS SPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRPTMPSGEWAPQS SAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVMN IGPSELEMNMGGPQYSQQQAPPNQTAPWPESILPIDQASFASQNRQPFGS SPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVSQ SQAVDPEQFSSQDSNIMLEQKAPVFPQQYASQAQMAQGSYSPMQDPNFHT MGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLMN QISNVSNVNLTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQV QQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGIS QQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWAQ GNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATNTGGMSSMNQMT GQISMTSVTSVPTSGLSSMGPEQVNDPALRGGNLFPNQLPGMDMIKQEGD | 1056 |
| 3D view using mol* of 780 (AA BP:389) | ||||||||||
 | ||||||||||
| PDB file (781) >>>781.pdbFusion protein BP residue: 390 CIF file (781) >>>781.cif | PAX3 | chr2 | 223084858 | - | NCOA2 | chr8 | 71060718 | - | MTTLAGAVPRMMRPGPGQNYPRSGFPLEVSTPLGQGRVNQLGGVFINGRP LPNHIRHKIVEMAHHGIRPCVISRQLRVSHGCVSKILCRYQETGSIRPGA IGGSKPKQVTTPDVEKKIEEYKRENPGMFSWEIRDKLLKDAVCDRNTVPS VSSISRILRSKFGKGEEEEADLERKEAEESEKKAKHSIDGILSERASAPQ SDEGSDIDSEPDLPLKRKQRRSRTTFTAEQLEELERAFERTHYPDIYTRE ELAQRAKLTEARVQVWFSNRRARWRKQAGANQLMAFNHLIPGGFPPTAMP TLPTYQLSETSYQPTSIPQAVSDPSSTVHRPQPLPPSTVHQSTIPSNPDS SSAYCLPSTRHGFSSYTDSFVPPSGPSNPMNPTIGNGLSPQPGSELDNLE EILDDLQNSQLPQLFPDTRPGAPAGSVDKQAIINDLMQLTAENSPVTPVG AQKTALRISQSTFNNPRPGQLGRLLPNQNLPLDITLQSPTGAGPFPPIRN SSPYSVIPQPGMMGNQGMIGNQGNLGNSSTGMIGNSASRPTMPSGEWAPQ SSAVRVTCAATTSAMNRPVQGGMIRNPAASIPMRPSSQPGQRQTLQSQVM NIGPSELEMNMGGPQYSQQQAPPNQTAPWPESILPIDQASFASQNRQPFG SSPDDLLCPHPAAESPSDEGALLDQLYLALRNFDGLEEIDRALGIPELVS QSQAVDPEQFSSQDSNIMLEQKAPVFPQQYASQAQMAQGSYSPMQDPNFH TMGQRPSYATLRMQPRPGLRPTGLVQNQPNQLRLQLQHRLQAQQNRQPLM NQISNVSNVNLTLRPGVPTQAPINAQMLAQRQREILNQHLRQRQMHQQQQ VQQRTLMMRGQGLNMTPSMVAPSGMPATMSNPRIPQANAQQFPFPPNYGI SQQPDPGFTGATTPQSPLMSPRMAHTQSPMMQQSQANPAYQAPSDINGWA QGNMGGNSMFSQQSPPHFGQQANTSMYSNNMNINVSMATNTGGMSSMNQM TGQISMTSVTSVPTSGLSSMGPEQVNDPALRGGNLFPNQLPGMDMIKQEG | 1057 |
| 3D view using mol* of 781 (AA BP:390) | ||||||||||
| ||||||||||
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
PAX3_pLDDT.png  |
NCOA2_pLDDT.png |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
PAX3_NCOA2_780_pLDDT.png (AA BP:389) |
PAX3_NCOA2_780_pLDDT_and_active_sites.png (AA BP:389) |
PAX3_NCOA2_780_violinplot.png (AA BP:389) |
PAX3_NCOA2_781_pLDDT.png (AA BP:390) |
PAX3_NCOA2_781_pLDDT_and_active_sites.png (AA BP:390) |
PAX3_NCOA2_781_violinplot.png (AA BP:390) |
Top |
Ramachandran Plot of Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| Fusion AA seq ID in FusionPDB and their Ramachandran plots |
| PAX3_NCOA2_780.png |
 |
| PAX3_NCOA2_781.png |
 |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| 780 | 1.0139 | 143 | 1.0598 | 481.229 | 0.6765 | 0.6664 | 0.8386 | 0.6832 | 0.8591 | 0.7953 | 0.7017 | Chain A: 27,28,29,30,31,39,43,44,45,46,47,48,49,50 ,51,52,53,54,55,56,58,76,77,78,79,82,85,86,89,98,9 9,101 |
| 781 | 0.9975 | 147 | 1.0309 | 467.852 | 0.6172 | 0.6682 | 0.8867 | 0.5646 | 0.9511 | 0.5936 | 0.6598 | Chain A: 27,28,29,30,31,39,40,43,44,45,46,47,48,49 ,50,51,52,54,55,56,76,77,78,79,82,85,86,89,98,99,1 01 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
| The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide. |
| Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. |
| ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
| ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9) |
| ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
| Toxicity information of individual drugs using eToxPred |
| ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| PAX3 | IPO13, SOX10, DAXX, MSX1, MEOX1, MEOX2, TBP, PSMD4, Rad23b, RAD23B, HDAC10, TRIM28, HDAC1, POU3F2, TAF1, PCTP, SPIN1, SKAP1, FOXE1, FZR1, NELL2, EGLN3, KRTAP8-1, KRTAP6-2, KIF20A, CIC, FOXO1, IGLC1, COL1A1, NTPCR, HBB, COL1A2, COL3A1, FITM2, MPL, S100A2, FBLN5, |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| PAX3 |  |
| NCOA2 |  |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to PAX3-NCOA2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to PAX3-NCOA2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PAX3 | C1847800 | Waardenburg Syndrome Type 1 | 33 | CLINGEN;CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | PAX3 | C0079661 | Klein's Syndrome | 16 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | PAX3 | C3266898 | Waardenburg Syndrome | 12 | CLINGEN;CTD_human;GENOMICS_ENGLAND |
| Hgene | PAX3 | C1852510 | Craniofacial deafness hand syndrome | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | PAX3 | C0038219 | Status Dysraphicus | 4 | CTD_human |
| Hgene | PAX3 | C0080178 | Spina Bifida | 4 | CTD_human |
| Hgene | PAX3 | C0266508 | Rachischisis | 4 | CTD_human |
| Hgene | PAX3 | C0011999 | Diastematomyelia | 3 | CTD_human |
| Hgene | PAX3 | C0027794 | Neural Tube Defects | 3 | CTD_human |
| Hgene | PAX3 | C0027806 | Neurenteric Cyst | 3 | CTD_human |
| Hgene | PAX3 | C0080218 | Tethered Cord Syndrome | 3 | CTD_human |
| Hgene | PAX3 | C0152234 | Iniencephaly | 3 | CTD_human |
| Hgene | PAX3 | C0152426 | Craniorachischisis | 3 | CTD_human |
| Hgene | PAX3 | C0266453 | Exencephaly | 3 | CTD_human |
| Hgene | PAX3 | C0344479 | Spinal Cord Myelodysplasia | 3 | CTD_human |
| Hgene | PAX3 | C0599973 | Waardenburg Anophthalmia Syndrome | 3 | ORPHANET |
| Hgene | PAX3 | C0702169 | Acrania | 3 | CTD_human |
| Hgene | PAX3 | C0206655 | Alveolar rhabdomyosarcoma | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Hgene | PAX3 | C0011052 | Prelingual Deafness | 1 | CTD_human |
| Hgene | PAX3 | C0011053 | Deafness | 1 | CTD_human |
| Hgene | PAX3 | C0018566 | Congenital Hand Deformities | 1 | CTD_human |
| Hgene | PAX3 | C0086395 | Hearing Loss, Extreme | 1 | CTD_human |
| Hgene | PAX3 | C0205944 | Sarcoma, Epithelioid | 1 | CTD_human |
| Hgene | PAX3 | C0205945 | Sarcoma, Spindle Cell | 1 | CTD_human |
| Hgene | PAX3 | C0265541 | Cranioschisis | 1 | CTD_human |
| Hgene | PAX3 | C0376634 | Craniofacial Abnormalities | 1 | CTD_human |
| Hgene | PAX3 | C0497552 | Congenital neurologic anomalies | 1 | CTD_human |
| Hgene | PAX3 | C0581883 | Complete Hearing Loss | 1 | CTD_human |
| Hgene | PAX3 | C0751068 | Deafness, Acquired | 1 | CTD_human |
| Hgene | PAX3 | C1261473 | Sarcoma | 1 | CTD_human |
| Hgene | PAX3 | C1710096 | Sinonasal undifferentiated carcinoma | 1 | CTD_human |
| Hgene | PAX3 | C3665473 | Bilateral Deafness | 1 | CTD_human |
| Hgene | PAX3 | C4082305 | Deaf Mutism | 1 | CTD_human |
| Tgene | NCOA2 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| Tgene | NCOA2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | NCOA2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | NCOA2 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| Tgene | NCOA2 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| Tgene | NCOA2 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Tgene | NCOA2 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies